Drugs / tyrosine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00302289 | Jan → Dec 2000 | obesity disorder | University of Copenhagen | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00302263 | Jan → Apr 2005 | obesity disorder | University of Copenhagen | Completed | No outcome recorded |
| Phase 2/3 | NCT00302276 | Jan → Jul 2004 | obesity disorder | University of Copenhagen | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07532330 | Aug 2025 → Feb 2026 | vitiligo | Minia University | Completed | No outcome recorded |
| — | NCT01219049 | Jan 2010 → Jan 2011 | fibromyalgia | Icahn School of Medicine at Mount Sinai | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tyrosine | “The objective of the present study was to investigate the acute and sub-chronic effect of a supplement containing green tea extract, capsaisin, caffeine, tyrosine and calcium...” NCT00302276 ↗4“Bioactive Metobes compound (green tea extract, tyrosine, caffeine and capsaicin) without calcium together with 5 mg propranolol.” NCT00302263 ↗ |
| Route | Topical | “Topical tyrosine 2% cream applied twice daily to the designated vitiligo patch for 3 months.” NCT07532330 ↗ |